A Novel Triazolopyrimidinone Derivative: A Portable Electrochemical Approach to Investigate DNA Interactions-Reference-Cited by-同舟云学术

A Novel Triazolopyrimidinone Derivative: A Portable Electrochemical Approach to Investigate DNA Interactions

Published:2023-12-28 Issue:4 Volume:44 Page:617-624
ISSN:2587-2680
Container-title:Cumhuriyet Science Journal
language:
Short-container-title:

Author:

ÇETİN Arif Engin¹^ORCID

Affiliation:

1. İzmir Biyotıp ve Genom Merkezi (İBG)

Abstract

In this study, a novel triazolopyrimidinone derivative, 2-(2-chlorophenyl)-5-(morpholinomethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one, abbreviated as CPD-1, was synthesized as a drug candidate. By employing electrochemical techniques, we analyzed the electrochemical behavior of this compound and its interactions with both single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA). Experimental parameters such as pH, concentration, scan rate, immobilization time were studied using Differential Pulse Voltammetry (DPV) and Cyclic Voltammetry (CV) to obtain the most precise analytical signals. We present an innovative approach to evaluate the toxicity effect of this drug candidate on DNA. We also propose a simplified equation to quantify toxicity effects based on changes in electrochemical signals, specifically peak current of guanine bases, before and after drug-DNA interactions. Our methodology contributes to the burgeoning field of electrochemical toxicity assessment and holds promise for advancing drug development and safety evaluation. Furthermore, stability tests for the drug candidate were conducted on different days. Notably, our investigation revealed significant alterations in guanine bases upon the interaction of CPD-1 with both ssDNA and dsDNA, underscoring the potential impact of these compounds on DNA structure. Based on our experimental data, we conclude that this molecule can be utilized as a drug due to its effects on DNA.

Publisher

Cumhuriyet University

Subject

General Medicine

Reference26 articles.

1. [1] Singh P.K., Choudhary S., Kashyap A., Verma H., Kapil S., Kumar M., Arora M., Silakari O., An exhaustive compilation on chemistry of triazolopyrimidine: A journey through decades, Bioorg. Chem., 88 (2019) 102919.

2. [2] Aliwaini S., Abu Thaher B., Al-Masri I., Shurrab N., El-Kurdi S., Schollmeyer D., Qeshta B., Ghunaim M., Csuk R., Laufer S., Kaiser L., Deigner H.P., Design, synthesis and biological evaluation of novel pyrazolo [1, 2, 4] triazolopyrimidine derivatives as potential anticancer agents, Molecules., 26(13) (2021) 4065.

3. [3] Bailey B.L., Nguyen W., Ngo A., Goodman C.D., Gancheva M.R., Favuzza P., Sanz L.M., Gamo F.J., Lowes K.N., McFadden G.I., Wilson D.W., Laleu B., Brand S., Jackson P.F., Cowman A.F., Sleebs B.E., Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity, Bioorg. Chem., 115 (2021) 105244.

4. [4] Ortiz Zacarías N.V., van Veldhoven J.P., den Hollander L.S., Dogan B., Openy J., Hsiao Y.Y., Lenselink E.B., Heitman L.H., IJzerman, A.P., Synthesis and pharmacological evaluation of triazolopyrimidinone derivatives as noncompetitive, intracellular antagonists for CC chemokine receptors 2 and 5, J. Med. Chem., 62(24) (2019) 11035-11053.

5. [5] Abd Al Moaty M.N., El Ashry E.S.H., Awad L.F., Ibrahim N.A., Abu-Serie M.M., Barakat A., Altowyan M.S., Teleb M., Enhancing the Anticancer Potential of Targeting Tumor-Associated Metalloenzymes via VEGFR Inhibition by New Triazolo [4, 3-a] pyrimidinone Acyclo C-Nucleosides Multitarget Agents, Molecules., 27(8) (2022) 2422.